oral masteron

Peptic ulcer history, bronchial asthma, a history of symptomatic cardiovascular disease, cerebrovascular disease and peripheral artery disease, dyslipidemia, progressive liver disease, hyperbilirubinemia, alcoholism, kidney failure, chronic heart failure, arterial hypertension, blood disorders, dehydration, diabetes, a history of the development of ulcerative lesions of the gastrointestinal tract, the presence of Helicobacter infection pylori, smoking, concomitant anticoagulant therapy oral masteron (such as warfarin), antiplatelet agents (for example, acetylsalicylic acid), oral corticosteroids (e.g., prednisone), selective reuptake inhibitors serotonin (e.g., citalopram, sertraline), prolonged use of NSAIDs.

  • Pregnancy and lactation
    The use of ketoprofen in the third trimester of pregnancy is contraindicated.
    In the first and second trimesters of pregnancy, use of the drug is only possible if the intended benefits to the mother outweighs the potential risk to the fetus.
    Before the drug during lactation should decide the issue of termination of breast feeding.DOSAGE AND ADMINISTRATION
    inside.
    Capsules of prolonged action Ketonal ® DNA should be taken during or after a meal, drinking water or milk (liquid volume must be at least 100 ml).
    The standard daily dose for adults and children over 15 years of age is 200 mg (1 long acting capsule)
    Maximum ketoprofen dose is 200 mg / day.

    SIDE EFFECTS
    The frequency of side effects described as very common (> 10%), common (> 1% <10%), non-proliferation (> 0.1% <1%), Rare (> 0.01% <0.1% ) and very rare (<0.01%). Allergic reactions: common – skin reactions (pruritus, urticaria), unextended – rhinitis, dyspnea, bronchospasm, angioedema, anaphylactoid reactions. Digestive system: common – dyspepsia (nausea, diarrhea, or constipation, flatulence, vomiting, decreased or increased appetite), abdominal pain, stomatitis, dry mouth, unextended (with prolonged use at high doses) – ulceration of the mucosa of the gastrointestinal tract, the liver; rare – perforation of the gastrointestinal tract and exacerbation of Crohn’s disease, melena, gastrointestinal bleeding. Central nervous system: common – headache, dizziness, sleep disturbance, fatigue, nervousness, nightmares; rare – headache, peripheral neuropathy; shadow rare – hallucinations, disorientation and speech disorder. Special Senses: Rare – ringing in the ears, change in taste, blurred vision, conjunctivitis. Cardiovascular system: unextended – tachycardia, hypertension, peripheral edema. The urinary system: rare – impaired function kidney, interstitial nephritis, nephrotic syndrome, hematuria (usually develops in people receiving long-term NSAIDs and diuretics). Other: rare – hemoptysis, menometrorrhagia. Laboratory findings: ketoprofen reduces platelet aggregation; transient increase in liver enzymes; rare – anemia, thrombocytopenia, agranulocytosis, purpura.

    Overdose
    As with other nonsteroidal anti-inflammatory drugs, an overdose of ketoprofen may experience nausea, vomiting, abdominal pain, vomiting of blood, melena, disturbance of consciousness, respiratory depression, convulsions, renal failure and renal failure.
    In case of overdose shown gastric lavage and . the use of activated carbon
    treatment – symptomatic; ketoprofen effect on the gastrointestinal tract can be reduced using H2 antagonist of histamine receptors, proton pump inhibitors and prostaglandins.

    INTERACTION WITH OTHER DRUG
    Ketoprofen may impair the effect of diuretics and antihypertensive drugs, and enhance the effect of oral hypoglycemic and certain anticonvulsants (phenytoin).
    The combined use with other non-steroidal anti-inflammatory drugs, salicylates, gpyukokortikosteroidami, ethanol increases the risk of adverse effects from the gastrointestinal tract.
    Co-administration with anticoagulants, thrombolytics, antiplatelet agents increases the risk of bleeding.
    with the simultaneous administration of nonsteroidal anti-inflammatory drugs with diuretics or angiotensin converting enzyme (ACE inhibitors) increases the risk of renal dysfunction.
    increases plasma concentration of cardiac glycosides, blockers of slow calcium channels , drugs lithium, cyclosporine, methotrexate.
    Nonsteroidal anti-inflammatory drugs may reduce the effectiveness of mifepristone. Receiving NSAIDs should be started no earlier than 8-12 days after withdrawal of mifepristone.

    Cautions
    Prolonged use of nonsteroidal anti-inflammatory drugs is necessary to monitor the state of the blood, as well as renal and hepatic function, especially in elderly patients (over 65 years).
    Care should be taken more frequently to control blood pressure in the application of ketoprofen in the treatment of patients with arterial hypertension , cardiovascular disorders, which result in fluid retention.
    Like other NSAIDs, ketoprofen may mask signs of infection.

    Effects on ability to concentrate:
    Data about the negative impact Ketonal ® DNA at recommended doses on the ability to drive a car or operate machinery is not. However, patients marking the unusual effects while taking Ketonal ® DNA, care must be taken when engaging in potentially hazardous activities that require high concentration and psychomotor speed oral masteron reactions.

    PACKAGING
    Capsules 200 mg sustained-release, 10 capsules in a blister; 1, 2 or 3 blisters with instruction on the medical application in a carton box.

    STORAGE
    In a dry, dark place at temperatures not above 30 ° C Keep out of reach of children.

    SHELF LIFE
    2 years.
    Do not use the drug after the expiry date.